Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
4.310
-0.090 (-2.05%)
At close: Feb 21, 2025, 4:00 PM
4.029
-0.281 (-6.51%)
After-hours: Feb 21, 2025, 7:42 PM EST
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2023. The number of employees increased by 3 or 50.00% compared to the previous year.
Employees
9
Change (1Y)
3
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,723,969
Market Cap
1.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
REVB News
- 4 weeks ago - Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - Business Wire
- 4 weeks ago - Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire
- 5 weeks ago - Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025 - Business Wire
- 6 weeks ago - Nasdaq Grants Revelation Biosciences Inc. Continued Listing - Business Wire
- 2 months ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds - Business Wire
- 2 months ago - Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND - Business Wire
- 3 months ago - Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - Business Wire
- 3 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - Business Wire